SEC For	m 4 FORM	4	UNITE	D ST	ΆΤΕ	ES S	ECUR	ITIE	ES AN	DE	ХСНА	NGE (	:ON	IMIS	SION					
						TES SECURITIES AND EXCHANGE COMMISSIC Washington, D.C. 20549											OMB APPROVAL			
Check this box if no longer subject to STATEMEN								IGE	ES IN I	BEI	ΙIP	- II	Number		3235-0287					
Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filec						l pursuant to Section 16(a) of the Securities Exchange Act of 1934											per res	erage burden ponse:	0.5	
						or Sec	tion 30(h) o	of the	Investme	nt Co	mpany Act	of 1940	001							
1. Name and Address of Reporting Person <sup>*</sup> <u>McNamara Peter</u>															5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 06/20/2024									Officer (give title Other (specify below)   Chief Scientific Officer					
C/O TECTONIC THERAPEUTIC, INC. 490 ARSENAL WAY, SUITE 210					4										6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WATERTOWN MA 02472					-										Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5	(Zip)			Rule 10b5-1(c) Transaction Indication															
,	,				Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
		Ta	able I - No	n-Der	ivati	ive S	ecurities	s Ac	quired,	Dis	posed c	of, or Be	nefi	cially	Owned					
1. Title of Security (Instr. 3) 2. Tran Date (Month				Date			2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Instr.		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4				5. Amount Securities Beneficial Owned Fo	Form (D) or		Direct Indirect	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount (A) or (D)		or P	rice	Reported Transactio				(Instr. 4)		
Common Stock 06/20					20/2	20/2024			A		10,68	10,688 A		(1)	10,6	10,688		D		
			Table II -				curities . Ils, warra								wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	ate, 4	I. Fransa Code (	iction	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis Expiration Dat (Month/Day/Ye		able and	ole and 7. Title and Amore of Securities		ount vative	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				6	Code	v	(A)	(D)			Expiration Date	Title	Amount or Number of Shares			Transaction(s) (Instr. 4)				
Employee Stock Option (Right to Buy)	\$2.38 <sup>(2)</sup>	06/20/2024			Α		37,959 <sup>(2)</sup>		(3)		06/27/2031	Common Stock			(2)(4)	37,959		D		
Employee Stock Option (Right to Buy)	\$2.98 <sup>(2)</sup>	06/20/2024			Α		32,065 <sup>(2)</sup>		(5)		06/26/2032	Common Stock			(2)(6)	32,065		D		
Employee Stock Option (Right to Buy)	\$5.38 <sup>(2)</sup>	06/20/2024			Α		18,704 <sup>(2)</sup>		(7)	(7) 11,		Common Stock 18,7		704 <sup>(2)</sup>	(2)(8)	18,704		D		
Employee Stock Option (Right to Buy)	\$16.8	06/20/2024	24		A		77,000		(9)		06/19/2034	Common Stock	77	,000	\$0 77,0		00	D		
								-												

## Explanation of Responses:

1. Received in exchange for 20,000 shares of common stock of Tectonic Therapeutic, Inc., a Delaware corporation ("Tectonic"), pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of Tectonic common stock was converted into the right to receive 0.534419990 shares of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO. Inc. to Tectonic Therapeutic, Inc.

2. Upon the closing of the Merger, each outstanding option to purchase shares of Tectonic common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tectonic stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split.

3. 25,796 of the shares subject to the option are immediately exercisable. The remainder of the shares subject to the option vest in 12 equal monthly installments beginning on July 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

4. Received in exchange for a stock option to acquire 71,029 shares of Tectonic common stock pursuant to the Merger Agreement.

5. The shares subject to the option vest in 48 equal monthly installments beginning on June 27, 2022, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

6. Received in exchange for a stock option to acquire 60,000 shares of Tectonic common stock pursuant to the Merger Agreement.

7. The shares subject to the option vest in 48 equal monthly installments beginning on December 1, 2023, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

8. Received in exchange for a stock option to acquire 35,000 shares of Tectonic common stock pursuant to the Merger Agreement.

9. The shares subject to the option vest as to 25% of the shares on June 20, 2025 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.

## /s/ Daniel Lochner, Attorney-in-Fact 06/24/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.